A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs AGN 190584 (Primary) ; Oxymetazoline (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors Allergan
- 03 Oct 2017 Planned End Date changed from 6 Jan 2018 to 22 Oct 2017.
- 03 Oct 2017 Planned primary completion date changed from 6 Jan 2018 to 22 Oct 2017.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.